Member Info for Sangijuelas1

I am glad that you love the stonk too. Hope you get your buy in before close

Yeah they are speeding up the common list updates so should be soon. Sounds like they are going to do a lot more testing

I will have to buy more now

I have been checking it every day. That's very meaningful

Yes yes yes

I can feel the sentiment starting to turn. The Bulls of Avacta are on the march

And hey it's Thursday, last chance to get in before the weekend

No i am just buying buying Avacta

Roche, listen up Alistair Smith is coming for you and your monkey antibodies.

180 close

I will be taking out a loan to get more as well. This is screaming buy.
Aim to get up to 50% of portfolio within the next week

Silly not to really at these bargain basement prices. I love this stonk

So if we all ramp it to the max their sentiment analysis tools might interpret as a buying signal

https://www.researchgate.net/publication/280567466_Predicting_Big_Movers_Based_on_Online_Stock_Forum_Sentiment_Analysis

Yeah it would be very easy to run sentiment analysis on the comment threads

https://blog.hubspot.com/service/sentiment-analysis-tools?toc-variant-a=

And yet you get 10 replies to the hedge fund shorters post ensuring that negativity stays at the top of the thread and that sensible folk who have filtered it still end up getting the gist.

It's almost like the ones that reply are working in tandem

How about you take your pathetic sob story to people in low income countries who have no access to the vaccine?

Yeah good to get the shout out in the article. The professor they quoted is not independent as he has his own microbiome company Axial Biotherapeutics, which are focused on CNS disease.
Could have referenced some of the clinical trial data to counter his point.

It's one of those things where a journalist is pumping something out quickly and people that have researched it over a longer period can spot the flaws.

Hadn't seen the article before. Not much depth to it.
Strange to contrast 4D with a start up company with a consortia approach when others like Finch and Seres are much further down the line.

The California professor sounded pretty clueless as he was referring to results in mouse models, when there have been extensive trials in humans.

It is always important to be really clear about the diverse approaches being employed to harness the microbiome. It's a spectrum from probiotic mixes, FMTs to the kind of single strain work 4D is doing. There is no reason why a diversity of approaches is not likely to emerge.

However, the more I understand about the 4D approach compared to others the more confident I feel.

2 reasons although I have others.
I noticed that Seres dropped their oncology trial for a consortia drug mainly because of problems in the FMT control group. (FMTs banned during Covid). So it seems they need to demonstrate efficacy with an additional cohort whereas 4D can stick to a normal placebo group.

Second, the regulators will expect to see a clear demonstration of functionality. Exactly how the drug works in the body. A lot easier to do with a single strain than with a consortia.

The article mentions engraftment and dysbiosis. Neither of which are relevant to the 4D approach. Don't look to engraft, rather have the drug enter the body, do its job and exit.

Not looking to treat general dysbiosis, more the actual condition being targeted. Discussed in the Investor call yesterday.

4d pharma had an OTC listing months before the main listing on Nasdaq.
So the OTC is unlikely to be the main Accustem listing. They can be used to generate liquidity prior to a main listing

Always good to remind people of Jupiter's short selling record

www.masterinvestor.co.uk/funds-and-investment-trusts/without-a-clunie-the-fund-manager-who-shorted-tesla-is-shown-the-door/amp/

Met one of their fund managers once. The main takeaway for me was how could he manage a fund when he couldn't even manage his dandruff, which his suit was covered in.